This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acorda Therapeutics Valuation

Is CDG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CDG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CDG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CDG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CDG?

Key metric: As CDG is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CDG. This is calculated by dividing CDG's market cap by their current revenue.
What is CDG's PS Ratio?
PS Ratio	0.1x
Sales	US$116.91m
Market Cap	US$15.22m

CDG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	18x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CDG's PS Ratio compare to its peers?

The above table shows the PS ratio for CDG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4x
MDG1 Medigene	3x	16.1%	€22.6m
CNW co.don	0.7x	n/a	€6.5m
PA8 Paion	0.2x	30.2%	€2.6m
HPHA Heidelberg Pharma	12.3x	16.6%	€103.9m
CDG Acorda Therapeutics	0.1x	n/a	€15.2m

Price-To-Sales vs Peers: CDG is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (13.1x).

Price to Sales Ratio vs Industry

How does CDG's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	21.8%
CDG Acorda Therapeutics	0.1x	n/a	US$15.22m
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	42.4%
CDG Acorda Therapeutics	0.1x	n/a	US$15.22m

No more companies

Price-To-Sales vs Industry: CDG is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is CDG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CDG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CDG's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.74

1.9%

-7.4%

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

6.7%

3.9%